Beth israel medical center
Brigham and womens hospital
Dana farber cancer institute
Hackensack university medical center
Jacobi medical center
Lenox hill hospital
Montefiore medical center
New york and presbyterian hospital
New york methodist hospital
North shore university hospital
Memorial Hospital For Cancer and Allied Diseases
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
Cancer Chemother. Pharmacol., Jul;70(1):201-5 (2012)
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Curr Treat Options Oncol., Jun;13(2):174-88 (2012)
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Eur. Urol., Nov;60(5):897-904 (2011)
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Clin. Cancer Res., Dec;16(24):6093-9 (2010)
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).
J Pain Symptom Manage., Mar;41(3):558-65 (2011)
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-ÎºB signalling.
Nat Commun., Jan;2:162 (2011)
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clin. Cancer Res., Feb;17(4):880-7 (2011)
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
J. Clin. Oncol., Jun;29(16):2191-8 (2011)
Developing imaging strategies for castration resistant prostate cancer.
Acta Oncol., Jun;50 Suppl 1:39-48 (2011)
Circulating tumor cells as biomarkers in prostate cancer.
Clin. Cancer Res., Jun;17(12):3903-12 (2011)
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
J. Clin. Oncol., Sep;29(27):3695-704 (2011)
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
J. Nucl. Med., Nov;52(11):1727-32 (2011)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer Chemother. Pharmacol., Apr;69(4):1089-97 (2012)
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
J. Clin. Oncol., Feb;30(5):519-24 (2012)
Prostate cancer in 2011: Hitting old targets better and identifying new targets.
Nat Rev Clin Oncol., Feb;9(2):70-2 (2012)
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
Pain Med., Mar;11(3):337-46 (2010)
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
J. Nucl. Med., Feb;51(2):183-92 (2010)
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Clin. Cancer Res., Apr;16(7):2115-21 (2010)
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Cancer Chemother. Pharmacol., May;66(1):181-9 (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet., Apr;375(9724):1437-46 (2010)